Safety and Effectiveness of the Alma System in Treating Primary Postpartum Hemorrhage

A prospective, non-randomized, feasibility pilot study that is intended to obtain information on the safety and effectiveness of the Alma System. Study population: Women with vaginal deliveries in a hospital setting who failed first-line therapies for postpartum hemorrhage. The main questions are: 1. Rate of device related SAEs up to six weeks following device treatment. 2. Rate of any observable damage to cervix, uterus or vagina during or immediately after device procedure. 3. Rate of occurrence of uterine inversion of folding during or immediately after device procedure. Main tasks for participants: * sign the informed Consent form and enrolment * In case of PPH, treatment with Alma * Participate in 2 follow-up visits After the treatment- 1st upon discharge and 2nd after 6 weeks.